Neuroscientific Biopharmaceuticals Ltd has released a press release.
Previous StemSmart Studies Demonstrate Clinical Response
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- NeuroScientific to Acquire Leading Stem Cell Technology
- 2024 Annual Report & Appendix 4E
- Appointment of Executive Director & FDA Pre-Ind Meeting
- NSB Receives A$2.2M Research & Development Tax Refund
- Resignation of CEO
Later from Neuroscientific Biopharmaceuticals
- StemSmart Acquisition Complete
- Experienced Cell Therapy Executive Appointed CEO
- Previous StemSmart Studies Support Renal Transplantation
- 2025 Annual Report & Appendix 4E
- Fourth Patient Commences StemSmart MSC Treatment
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals